← Leaderboards
Andrei L Gartel
University Of Illinois At Chicago
$3,460,217
Attributed
$3,460,217
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $573K · FY2008–22$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,460,217 · 6
By mechanism
R01$1,906,371 · 2
R21$1,553,846 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisTumor XenograftMouse ModelPharmaceutical PreparationsTranscription FactorGenesXenograft ProcedureTissuesDoseCancer CellResearch StudyResistanceNeoplastic CellToxic EffectMolecularOncogenicAntineoplastic AgentsIn VitroCellsMammalian CellIn VivoFamilyMalignant NeoplasmsInhibitor/Antagonist
Grant awards (14)
Targeting FOXM1 in chemo-resistant monocytic AML$207,326
R21 · FY2022 · TR · contact PI
Targeting FOXM1 in chemo-resistant monocytic AML$263,793
R21 · FY2021 · TR · contact PI
Cytoplasmic FOXM1 contributes to the higher complete remission and longer overall survival of AML patients after chemotherapy$173,873
R21 · FY2016 · CA · contact PI
Cytoplasmic FOXM1 contributes to the higher complete remission and longer overall survival of AML patients after chemotherapy$208,539
R21 · FY2015 · CA · contact PI
Inhibition of matrix proteases to sensitize medulloblastoma cells to radiation$297,042
R01 · FY2013 · CA · contact PI
Evaluation of novel FoxM1 inhibitors against liver cancer$316,002
R01 · FY2012 · CA · contact PI
Evaluation of novel FoxM1 inhibitors against liver cancer$316,002
R01 · FY2011 · CA · contact PI
Evaluation of novel FoxM1 inhibitors against liver cancer$325,775
R01 · FY2010 · CA · contact PI
Evaluation of novel FoxM1 inhibitors against liver cancer$325,775
R01 · FY2009 · CA · contact PI
The role of FoxM1 in pancreatic cancer$247,275
R21 · FY2009 · CA · contact PI
Evaluation of novel FoxM1 inhibitors against liver cancer$325,775
R01 · FY2008 · CA · contact PI
The role of FoxM1 in pancreatic cancer$141,300
R21 · FY2008 · CA · contact PI
P21 transcriptional inhibitors as proapoptotic compounds$155,870
R21 · FY2003 · CA
P21 transcriptional inhibitors as proapoptotic compounds$155,870
R21 · FY2002 · CA